首頁 > 市場調查報告書 > 醫療設備

體外診斷生技設備

市場調查報告書

商品編碼

1529027

化學發光免疫分析市場、副產品（儀器、消耗品、試劑[發光體、酵素標記]、軟體和服務）、技術（CLEIA、ECLI）、樣品類型、應用、最終用途 - 全球預測 2024 - 2032

Chemiluminescence Immunoassay Market, By Product (Instrument, Consumable, Reagent [Luminophore, Enzymatic Marker], Software & Service), Technology (CLEIA, ECLI), Sample Type, Application, End-use - Global Forecast 2024 - 2032

出版日期: 2024年05月14日 | 出版商:

Global Market Insights Inc. | 英文 278 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

全球化學發光免疫分析市場在 2024 年至 2032 年間的複合年成長率將達到 7.3%，主要得益於領先公司推出的產品數量不斷增加。這些產品的特點通常是創新和增強的檢測試劑盒，可提供卓越的靈敏度、特異性和更快的周轉時間。診斷產業的主要參與者不斷投資於研發，推出下一代 CLIA 系統，以滿足臨床實驗室和研究機構不斷變化的需求。

例如，2024 年 1 月，在印度醫療保健技術的突破性發展中，總部位於高知的 Agappe 公司推出了首款本土製造的 HX 系列血液學設備，以及人工智慧驅動的免疫學 CLIA 分析儀 Mispa i200。這標誌著診斷和患者護理新時代的開始。

這些新產品通常採用自動化和多重功能等先進技術，可簡化實驗室工作流程並提高效率。攜帶式和方便用戶使用型 CLIA 設備的推出也擴大了市場範圍，使小型實驗室和照護端環境更容易進行這些測定。

化學發光免疫分析產業的總體規模根據產品、技術、樣品類型、應用、最終用途和地區進行分類。

由於儀器的進步，化學發光免疫分析 (CLIA) 市場的需求不斷增加。現代 CLIA 儀器具有更高的靈敏度、特異性和效率，使其成為臨床診斷和研究不可或缺的一部分。這些儀器的特點是自動化和高通量能力，可簡化實驗室工作流程並提供快速、準確的結果。 CLIA儀器中連接複用和人工智慧等尖端技術的整合進一步拓寬了其應用範圍，從檢測傳染病到監測慢性病。隨著醫療保健提供者尋求可靠、高效的診斷工具，對複雜 CLIA 儀器的需求持續成長，推動市場擴張。

化學發光免疫分析（CLIA）市場受到電化學發光免疫分析（ECLIA）技術不斷成長的需求的顯著推動。 ECLIA 具有卓越的靈敏度、特異性和精確度，使其成為臨床診斷和研究的首選。該技術能夠提供快速、準確的結果，對於檢測各種疾病（包括傳染病和癌症）至關重要。 ECLIA 系統的自動化和高通量能力提高了實驗室效率和工作流程。隨著醫療保健行業擴大採用先進的診斷方法來改善患者的治療效果，對 ECLIA 的需求持續成長，從而促進了 CLIA 市場的整體擴張。

在醫療保健基礎設施的進步和對準確診斷解決方案的需求增加的推動下，亞太地區化學發光免疫分析 (CLIA) 市場正在經歷顯著成長。慢性病和傳染病的盛行率不斷上升，需要可靠、快速的檢測方法，從而推動了 CLIA 技術的採用。政府措施和醫療保健支出的增加進一步推動了市場的發展，同時人們對先進診斷工具的認知和採用也不斷提高。該地區不斷擴大的醫學研究和開發活動也促成了這一激增。因此，在這些醫療保健進步和不斷成長的診斷需求的推動下，亞太地區 CLIA 市場有望大幅擴張。

產業生態系統分析
產業影響力
- 成長動力
  - 慢性病和傳染病的盛行率不斷上升
  - 化學發光免疫分析技術的進展
  - 擴大藥物開發和臨床研究的應用
- 產業陷阱與挑戰
  - 嚴格的監管場景
  - 設備成本高
成長潛力分析
技術景觀
監管環境
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
競爭定位矩陣
戰略展望矩陣

第 5 章：市場估計與預測：按產品分類，2021 - 2032 年

主要趨勢
儀器儀表
- 自動化
- 半自動化
耗材
試劑
- 發光體標記
- 酵素標記物
軟體與服務

第 6 章：市場估計與預測：按技術分類，2021 - 2032 年

主要趨勢
化學發光酶技術（CLEIA）
電化學發光免疫分析 (ECLI)
微粒化學發光免疫分析

第 7 章：市場估計與預測：按樣本類型，2021 - 2032

主要趨勢
血
尿
唾液
其他樣品類型

第 8 章：市場估計與預測：按應用分類，2021 - 2032

主要趨勢
治療藥物監測
腫瘤學
心臟病學
內分泌科
傳染病
自體免疫疾病
血液篩檢
毒理學
新生兒篩檢
代謝紊亂
胃腸病學
呼吸系統
其他應用

第 9 章：市場估計與預測：依最終用途，2021 - 2032 年

主要趨勢
醫院
臨床實驗室
製藥和生物技術公司
其他最終用戶

第 10 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 11 章：公司簡介

Abbott Laboratories
Bio-Rad Laboratories, Inc.
Danaher corporation
DiaSorin S.p.A
Eurofins Scientific SE
F. Hoffmann-La Roche Ltd
H.U. Group Holdings, Inc.
Maccura Biotechnology Co., Ltd.
Revvity, Inc.
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
Shenzhen New Industries Biomedical Engineering Co., Ltd.
Siemens Healthineers AG
Thermo Fisher Scientific Inc.
Tosoh Corporation
Werfen

簡介目錄

Product Code: 9477

Global Chemiluminescence Immunoassay Market will witness a 7.3% CAGR between 2024 and 2032, driven significantly by the increasing number of product launches from leading companies. These launches are often characterized by innovative and enhanced assay kits that offer superior sensitivity, specificity, and faster turnaround times. Major players in the diagnostics industry are continuously investing in research and development to introduce next-generation CLIA systems that cater to the evolving needs of clinical laboratories and research institutions.

For instance, in January 2024, in a groundbreaking development for Indian healthcare technology, Agappe, a Kochi-based firm introduced its first indigenously manufactured HX series hematology equipment, along with the AI-powered Immunology CLIA analyzer, the Mispa i200. This marked the beginning of a new era in diagnostics and patient care.

These new products often incorporate advanced technologies, such as automation and multiplexing capabilities, which streamline laboratory workflows and improve efficiency. The introduction of portable and user-friendly CLIA devices has also expanded the market's reach, making these assays more accessible to smaller laboratories and point-of-care settings.

The overall Chemiluminescence Immunoassay Industry size is classified based on the product, technology, sample type, application, end-use, and region.

The chemiluminescence immunoassay (CLIA) market is experiencing increased demand driven by advancements in instruments. Modern CLIA instruments offer enhanced sensitivity, specificity, and efficiency, making them indispensable for clinical diagnostics and research. These instruments, characterized by their automation and high throughput capabilities, streamline laboratory workflows and provide rapid, accurate results. The integration of cutting-edge technologies, such as multiplexing and AI, in CLIA instruments has further broadened their application scope, from detecting infectious diseases to monitoring chronic conditions. As healthcare providers seek reliable and efficient diagnostic tools, the demand for sophisticated CLIA instruments continues to grow, propelling market expansion.

The chemiluminescence immunoassay (CLIA) market is significantly driven by the rising demand for electrochemiluminescence immunoassay (ECLIA) technologies. ECLIA offers superior sensitivity, specificity, and precision, making it a preferred choice in clinical diagnostics and research. This technology's ability to deliver rapid and accurate results is crucial for detecting various diseases, including infectious diseases and cancer. The automation and high throughput capabilities of ECLIA systems enhance laboratory efficiency and workflow. As the healthcare sector increasingly adopts advanced diagnostic methods for better patient outcomes, the demand for ECLIA continues to grow, contributing to the overall expansion of the CLIA market.

Asia Pacific chemiluminescence immunoassay (CLIA) market is experiencing significant growth, driven by advancements in healthcare infrastructure and increased demand for accurate diagnostic solutions. The rising prevalence of chronic and infectious diseases necessitates reliable and rapid testing methods, propelling the adoption of CLIA technology. Government initiatives and increased healthcare spending further boost the market, alongside growing awareness and adoption of advanced diagnostic tools. The region's expanding medical research and development activities also contribute to this surge. Consequently, the Asia Pacific CLIA market is poised for substantial expansion, driven by these healthcare advancements and increasing diagnostic needs.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360°synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing prevalence of chronic and infectious diseases
  - 3.2.1.2 Technological advancements in chemiluminescence immunoassay
  - 3.2.1.3 Expanding applications in drug development and clinical research
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Stringent regulatory scenario
  - 3.2.2.2 High cost of devices
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Instruments
- 5.2.1 Automated
- 5.2.2 Semi-automated
5.3 Consumables
5.4 Reagents
- 5.4.1 Luminophore markers
- 5.4.2 Enzymatic markers
5.5 Software & services

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Chemiluminescence enzyme technology (CLEIA)
6.3 Electrochemiluminescence immunoassay (ECLI)
6.4 Microparticle chemiluminescence immunoassay

Chapter 7 Market Estimates and Forecast, By Sample Type, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Blood
7.3 Urine
7.4 Saliva
7.5 Other sample types

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Therapeutic drug monitoring
8.3 Oncology
8.4 Cardiology
8.5 Endocrinology
8.6 Infectious diseases
8.7 Autoimmune diseases
8.8 Blood screening
8.9 Toxicology
8.10 Newborn screening
8.11 Metabolic disorder
8.12 Gastroenterology
8.13 Respiratory
8.14 Other applications

Chapter 9 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 Hospitals
9.3 Clinical laboratories
9.4 Pharmaceutical & biotechnology companies
9.5 Other end-users

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Netherlands
- 10.3.7 Rest of Europe
10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Argentina
- 10.5.4 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE
- 10.6.4 Rest of Middle East and Africa